Unveiled as a preview in 2024, Tonasulike-D [1] is claimed by Kokuma to deliver safe and visible reduction of hyperpigmentation while enhancing skin radiance across all tested skin types.

This patented, AI-discovered active ingredient leverages a dual, synergistic mechanism of action. It works upstream to reduce melanin production and downstream to prevent melanin transfer. At the IFSCC 2025 Congress and the Cosmetic 360 trade show, Kokuma presented new clinical efficacy data demonstrating results at a concentration of just 0.01%.

“By leveraging AI and biotech, we uncovered a potent new ingredient that delivers clinical results safely, setting new standards for depigmenting and brightening ingredients,” said Yannick Quesnel, Ph.D., Chief Scientific Officer and Co-founder of Kokuma.

Clinically proven performance

Both in vitro and ex vivo studies have shown that Tonasulike-D delivers visible and measurable results — even at an exceptionally low concentration of 0.01% — in reducing hyperpigmentation and brightening the skin.

A 12-Week randomized single-blind controlled study (60 volunteers, Skin Types III-V, ages: 30-75) has shown pigmentation reduction and brightness improvement by week 8 for 100% of the participants. The first visible changes appear at day 21, with continued improvement through week 12.

After 12 weeks, studies showed a 17% decrease in dark spot pigmentation accompanied by a significant improvement in skin tone evenness (ITA) in both Caucasian and Asian skin types, as well as up to 24% increase in skin brightness (ITA) on dark skin.

Furthermore, in vitro and ex vivo tests have shown a 86% reduction in melanin production (lab study on human melanocytes) and a 45% reduction in melanin content (human skin explants).

Dual action

Tonasulike-D was discovered using Kokuma’s AI platform, applying pharmaceutical-style in-silico predictive tools to identify high-potential, previously untapped biological targets. By combining public and proprietary data integration, AI-based predictions (e.g., solubility, lipophilicity, skin penetration), mechanistic insight, safety profiling and IP landscape mapping, Kokuma’s experts identified and validated their top-performing molecule.

Tonasulike-D acts through two complementary mechanisms: it reduces melanin production by lowering the levels of key enzymes involved in melanogenesis, such as tyrosinase, and it inhibits melanin transfer to the basal layers of the epidermis by modulating the NF-κB signaling pathway—an essential regulator of pigment transfer from melanocytes to keratinocytes.

According to Kokuma, the combination of these actions lighten the skin and existing dark spots without irritation, sensitivity, or compromising skin health.

“After three years of R&D, lab testing, and clinical trials, we’re ready to bring Tonasulike-D to the market starting this fall,” announced Alexandre Jouve, Pharm.D., CEO and Co-founder of Kokuma.

“Formulators are already enthusiastic about its high efficacy at a low concentration, which makes it compatible with a wide range of formats—from face serums to hand and body care. We’re working hand-in-hand with brands to adapt to their needs,” added Olivier Fontaine, Pharm.D., Board Member and Advisor.